Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;16(5):6691-6696.
doi: 10.3892/ol.2018.9497. Epub 2018 Sep 25.

Precursor B cell lymphoid blast crisis of chronic myeloid leukemia with novel chromosomal abnormalities: A case report

Affiliations

Precursor B cell lymphoid blast crisis of chronic myeloid leukemia with novel chromosomal abnormalities: A case report

Hamoud Al-Khallaf et al. Oncol Lett. 2018 Nov.

Abstract

Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder. It is characterized by the presence of the Philadelphia (Ph) chromosome, t(9;22)(q34.1;q11.2), which carries the BCR-ABL1 fusion gene. Tyrosine kinase inhibitors (TKIs) have markedly changed the treatment approach of CML and have become the first-line agents for almost all CML patients. However, certain patients experience resistance to these medications, which occurs through several mechanisms, including the accumulation of TKI-resistant chromosomal abnormalities. The present study reports a case of a 27-year-old Saudi male with CML receiving TKI treatment, who presented with precursor B-cell lymphoblastic crisis demonstrating the presence of the novel combined chromosomal abnormalities; non-Ph der(22), i(9) and der(20), carrying the BCR-ABL1 fusion gene. This case report adds to the literature on novel TKI-resistance-conferring chromosomal abnormalities and links them to precursor B-cell lymphoblastic crisis.

Keywords: blast crisis; chronic myeloid leukemia; cytogenetic abnormalities; precursor B cell; tyrosine kinase inhibitor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Giemsa-banding karyogram of the patient's bone marrow. Isochromosome 9q, derivative chromosomes 20 and 22 (red arrows) are presented, where the extra material on 20 containing BCR-ABL1 fusion is derived from chromosome 22. (B) Ideogram of all chromosomal abnormalities observed in this case with breakpoints marked.
Figure 2.
Figure 2.
FISH analysis of one metaphase and one interphase nucleus. (A) Showing two ABL1 (red) signals, one BCR signal (green), and two fusion gene BCR-ABL1 signals (yellow). (B) Labelled inverted image showing two ABL1 signals on the two long arms of isochromosome 9 (red), one BCR signal (green) on chromosome 22, and two fusion gene BCR-ABL1 signals (yellow) one on the long arm of der 9 and one on that of der 20, confirming the abnormalities seen on the karyogram. (C) Non-labelled inverted image identifying the chromosomes containing the signals.
Figure 3.
Figure 3.
Ideogram illustrating the formation of the cytogenetic abnormalities observed in this case. (A) Ideogram of the proposed first step where a reciprocal translocation between chromosomes 9 and 22 (red arrows) formed the Philadelphia (Ph) and derivative (der) 9 chromosomes. (B) Ideogram of the proposed second step where a reciprocal translocation (bidirectional red arrow) between chromosome 20 and Ph chromosome formed der(22) and der(20) chromosomes (the latter carrying the BCR-ABL1 fusion gene). (C) Isochromosome 9q [i(9q)] formation as an additional cytogenetic abnormality that did not necessarily occur in this order.

Similar articles

Cited by

References

    1. Kuru D, Argüden Tarkan Y, Ar M, Çırakoğlu A, Öngören Ş, Yılmaz Ş, Eşkazan A, Deviren A, Soysal T, Hacıhanefioğlu S, Ülkü B. Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients. Turk J Haematol. 2011;28:186–192. doi: 10.5152/tjh.2011.52. - DOI - PubMed
    1. Aliano S, Cirmena G, Fugazza G, Bruzzone R, Palermo C, Sessarego M. Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy. Leuk Res Rep. 2013;2:75–78. - PMC - PubMed
    1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;17:1330–1340. doi: 10.1056/NEJM199904293401706. - DOI - PubMed
    1. Cervantes F, Villamor N, Esteve J, Montoto S, Rives S, Rozman C, Montserrat E. ‘Lymphoid’ blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol. 1998;100:123–128. doi: 10.1046/j.1365-2141.1998.00542.x. - DOI - PubMed
    1. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009;15:7519–7527. doi: 10.1158/1078-0432.CCR-09-1068. - DOI - PubMed